Related Experiment Video
Updated: Jun 21, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Pediatric allergy medications: review of currently available formulations
1Royal National Throat Nose & Ear Hospital, London WC1X 8DA, UK. g.scadding@ucl.ac.uk
Insights
Pediatric allergic rhinitis (AR) treatments face challenges in administration and formulation. New sugar-free and dye-free options are emerging to improve safety and convenience for children with AR.
Area of Science:
- Pediatric Allergy and Immunology
- Pharmaceutical Sciences
- Public Health
Background:
- Allergic rhinitis (AR) impacts approximately 50% of the global pediatric population.
- AR significantly impairs children's quality of life, affecting sleep, school attendance, and academic performance.
Purpose of the Study:
- To review available medications for pediatric allergic rhinitis (AR).
- To assess parental and healthcare professional attitudes towards pediatric AR medications.
- To identify current recommendations and labeling requirements for pediatric AR treatments.
Main Methods:
- Systematic review of guidelines from international organizations and governmental websites.
- Medline search utilizing terms related to pediatric medication ingredients and prescribing habits.
- Evaluation of traditional and novel formulations for pediatric AR treatment.
Main Results:
- Increasing demand for safer, more convenient pediatric medicines, particularly sugar-free and dye-free options.
- Availability of diverse formulations like granules, filmstrips, and fast-dissolving tablets for pediatric use.
- Regulatory agencies recommend avoiding sugar in pediatric medicines.
Conclusions:
- Limited well-designed trials exist for pediatric AR treatments.
- Safety, tolerability, convenience, and acceptance are crucial for long-term AR management in children.
- Potential for social response bias in parental and physician perceptions of medication ingredients.
Background:
Allergy affects about 50% of the pediatric population globally. Allergic rhinitis (AR), one form of allergy, causes considerable impairment in quality of life, including disruption of sleep and, in children, interference with school attendance and performance.
Scope:
Traditional formulations and delivery systems - tablets, capsules, or intranasal sprays - successfully used by adults for treatment of AR may not be as easily administered in children. Liquid oral medications are more readily taken by children but contain sugars and excipients; they can also be inconvenient with less accurate dosing and are associated with dental caries and gastrointestinal upset.
Methodology:
This review evaluated medications for treatment of AR currently available for pediatric patients and identified the attitudes of parents and health care professionals toward these medications. Guidelines from international organizations and governmental websites were reviewed for recommendations and product labeling requirements. A Medline search was conducted using the terms dyes, excipients, palatability, prescribing habits, sugar, among others.
Findings:
In recent years, governmental regulatory agencies and professional organizations in Europe and the United States have recommended avoidance of sugar in pediatric medicines and required stricter labeling of their ingredients. Public awareness about the adverse effects of sugar and some excipients has also increased, and parents more frequently express the desire for safer and more convenient medicines for their children. In response, more sugar-free, dye-free liquid medicines and other formulations, such as granules, filmstrips, chewable tablets, fast-dissolving tablets, and drops, are becoming available for pediatric use.
Limitations:
Data from well-designed trials conducted in children for the treatment of AR are lacking. In addition, the possibility of a social response bias may exist for parents and physicians about sugar and other ingredients in children's medications.
Conclusion:
Treatment for AR is often long-term, particularly in persistent AR; therefore, safety, tolerability, convenience, and patient/parental acceptance are important considerations when deciding which medication to prescribe.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Reactions: Anaphylaxis
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Allergic Reactions

